Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lyell Immunopharma (LYEL) Free Cash Flow (2020 - 2025)

Lyell Immunopharma's Free Cash Flow history spans 6 years, with the latest figure at -$28.2 million for Q3 2025.

  • For Q3 2025, Free Cash Flow rose 18.85% year-over-year to -$28.2 million; the TTM value through Sep 2025 reached -$165.1 million, down 7.81%, while the annual FY2024 figure was -$162.5 million, 0.72% up from the prior year.
  • Free Cash Flow for Q3 2025 was -$28.2 million at Lyell Immunopharma, up from -$34.7 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at -$23.8 million in Q3 2022 and bottomed at -$74.1 million in Q3 2021.
  • The 5-year median for Free Cash Flow is -$42.2 million (2024), against an average of -$43.7 million.
  • The largest annual shift saw Free Cash Flow crashed 184.01% in 2021 before it skyrocketed 67.95% in 2022.
  • A 5-year view of Free Cash Flow shows it stood at -$43.5 million in 2021, then crashed by 40.25% to -$61.0 million in 2022, then surged by 37.68% to -$38.0 million in 2023, then fell by 24.63% to -$47.4 million in 2024, then soared by 40.54% to -$28.2 million in 2025.
  • Per Business Quant, the three most recent readings for LYEL's Free Cash Flow are -$28.2 million (Q3 2025), -$34.7 million (Q2 2025), and -$54.9 million (Q1 2025).